MSDL vs VRTX · P/E 15, $1.29B cap vs P/E 30, rev $3.33B
Morgan Stanley Direct Lending Fund (MSDL) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Morgan Stanley Direct Lending Fund (MSDL) is a asset management company listed on NYSE.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
MSDL does not have a complete income-statement cache yet.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
MSDL currently screens at market cap $1.29B and trailing P/E 15.0. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the MSDL and VRTX stock pages for the full models.
Not investment advice.